← Back to Screener
Enliven Therapeutics, Inc. Common Stock (ELVN)
Price$45.34
Favorite Metrics
Price vs S&P 500 (26W)112.30%
Price vs S&P 500 (4W)55.46%
Market Capitalization$2.63B
All Metrics
Book Value / Share (Quarterly)$7.73
P/TBV (Annual)6.60x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.19
Price vs S&P 500 (YTD)182.75%
EPS (TTM)$-1.86
10-Day Avg Trading Volume1.28M
EPS Excl Extra (TTM)$-1.86
EPS (Annual)$-1.83
ROI (Annual)-22.56%
Cash / Share (Quarterly)$7.78
ROA (Last FY)-21.78%
EBITD / Share (TTM)$-2.11
ROE (5Y Avg)-27.62%
Cash Flow / Share (Annual)$-1.19
P/B Ratio5.72x
P/B Ratio (Quarterly)1.99x
Net Income / Employee (Annual)$-2
ROA (TTM)-23.39%
EV / EBITDA (TTM)676.29x
EPS Incl Extra (Annual)$-1.83
Current Ratio (Annual)28.66x
Quick Ratio (Quarterly)27.92x
3-Month Avg Trading Volume1.21M
52-Week Price Return155.67%
EV / Free Cash Flow (Annual)319.79x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.35
52-Week High$46.31
EPS Excl Extra (Annual)$-1.83
CapEx CAGR (5Y)51.19%
Tangible BV CAGR (5Y)52.86%
26-Week Price Return116.29%
Quick Ratio (Annual)27.92x
13-Week Price Return75.59%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)28.66x
Enterprise Value$2,529.332
Book Value / Share Growth (5Y)57.49%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$7.78
3-Month Return Std Dev66.96%
Net Income / Employee (TTM)$-2
ROE (Last FY)-22.56%
EPS Basic Excl Extra (Annual)$-1.83
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.86
ROI (TTM)-24.22%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$20.43
Price vs S&P 500 (52W)125.84%
Year-to-Date Return185.39%
5-Day Price Return-3.60%
EPS Normalized (Annual)$-1.83
ROA (5Y Avg)-25.70%
Month-to-Date Return12.12%
Cash Flow / Share (TTM)$-0.72
EBITD / Share (Annual)$-2.11
LT Debt / Equity (Annual)0.08x
ROI (5Y Avg)-27.62%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.86
P/TBV (Quarterly)1.84x
P/B Ratio (Annual)1.99x
Book Value / Share (Annual)$7.73
Price vs S&P 500 (13W)74.90%
Beta0.60x
Revenue / Share (TTM)$0.00
ROE (TTM)-24.22%
52-Week Low$14.79
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ELVNEnliven Therapeutics, Inc. Common Stock | — | — | — | — | $45.34 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule targeted therapies for cancer. Its pipeline includes ELVN-001, which targets BCR-ABL fusion in chronic myeloid leukemia, and ELVN-002, a HER2 inhibitor designed to address both wild-type and mutant forms of the protein.